(Q43172781)

English

Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks

scientific article published in November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

0 references

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

adherence (medicine)

1 reference

based on heuristic

inferred from title

author name string

Dushyantha Jayaweera

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Edwin Dejesus

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Kim L Nguyen

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Kristy Grimm

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

David Butcher

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Daniel W Seekins

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

HIV Clinical Trials

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

375-384

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Adherence to antiretroviral therapy: an update of current concepts

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Adherence in antiretroviral therapy: a review of qualitative studies

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Efavirenz for HIV-1 infection in adults: an overview

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQOL-HIV Validation Group. Medical Outcomes Study HIV Health Survey.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Strategies for improving patient adherence to therapy and long-term patient outcomes

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Adherence to HAART Regimens

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.

1 reference

https://api.crossref.org/works/10.1310%2FHCT1006-375

21 January 2018

Identifiers

10.1310/HCT1006-375

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43172781&oldid=1982848680"